Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0047 | 0.0032 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.091 | 0.367 | 0.366 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0091 | 0.0091 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0169 | 0.0169 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0047 | 1 |
Toxoplasma gondii | sedoheptulose-1,7-bisphosphatase | 0.091 | 0.367 | 0.366 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0047 | 0.0032 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0764 | 0.0764 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0047 | 0.0032 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.2448 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0764 | 0.0764 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.2448 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.0047 | 0.0047 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0015 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0015 | 0.5 |
Echinococcus multilocularis | geminin | 0.0205 | 0.0764 | 0.0764 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0015 | 0.0015 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0047 | 1 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.2448 | 1 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0015 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.0015 | 0.0015 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0015 | 0.0015 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0015 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0015 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0169 | 0.0169 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0047 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0015 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.2448 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0169 | 0.0169 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0015 | 0.5 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.2448 | 1 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0091 | 0.0091 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.2448 | 1 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.0047 | 0.0032 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0169 | 0.0169 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.2448 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0047 | 0.0032 |
Leishmania major | 0.2448 | 1 | 1 | |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.091 | 0.367 | 0.366 |
Brugia malayi | hypothetical protein | 0.002 | 0.0002 | 0.0002 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0015 | 0.0015 |
Echinococcus granulosus | geminin | 0.0205 | 0.0764 | 0.0764 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0015 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.0091 | 0.0091 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.0047 | 0.0047 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0015 | 0.0015 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0015 | 0.0015 |
Toxoplasma gondii | fructose-bisphospatase I | 0.091 | 0.367 | 0.366 |
Trypanosoma brucei | sedoheptulose-1,7-bisphosphatase | 0.091 | 0.367 | 0.366 |
Toxoplasma gondii | fructose-bisphospatase II | 0.2448 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1889 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.3162 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.5012 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.4716 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 1.6511 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 2.5119 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.5119 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 12.9953 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.